Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 3

2(28.6%)

Phase 2

1(14.3%)

7Total

Phase 1(4)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07565428Phase 3Recruiting

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

Role: lead

NCT06107803Phase 1Completed

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

Role: lead

NCT03397134Phase 3Completed

Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia

Role: lead

NCT03446846Phase 2Completed

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

Role: lead

NCT03038646Phase 1Completed

A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

Role: lead

NCT03072056Phase 1Completed

A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers

Role: lead

NCT02232529Phase 1Completed

Pharmacokinetic Study of MIN-101 in Healthy Subjects

Role: lead

All 7 trials loaded